bortezomib + dexamethasone + cyclophosphamide + lenalidomide

Bortezomib + dexamethasone + cyclophosphamide + lenalidomide is a four-drug combination regimen used primarily in the treatment of multiple myeloma, especially as a frontline or induction therapy. The regimen combines: - **Bortezomib** (a proteasome inhibitor), which blocks the 26S proteasome, disrupting protein degradation and inducing apoptosis in myeloma cells - **Dexamethasone** (a synthetic corticosteroid), which exerts anti-inflammatory and immunosuppressive effects, supporting anti-myeloma activity through lymphocyte suppression - **Cyclophosphamide** (an alkylating agent), which causes DNA cross-linking and apoptosis, thereby suppressing malignant plasma cell proliferation - **Lenalidomide** (an immunomodulatory agent), which promotes tumor cell apoptosis, inhibits angiogenesis, and modifies the immune microenvironment The VDCR regimen is noted for its high overall response rates and is considered well-tolerated based on clinical studies, though hematologic toxicities and neuropathy can occur.

Other names

VDCR